CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Income Statement [Abstract]
Net revenues	$ 133,517	$ 115,925	$ 268,212	$ 217,753	$ 494,366
Cost of revenues	28,599	25,474	54,984	49,970	106,501
Gross profit	104,918	90,451	213,228	167,783	387,865
Operating costs and expenses:
Research, development and clinical trials	50,315	29,918	96,231	55,190	132,010
Sales and marketing	34,138	28,461	65,495	57,294	118,017
General and administrative	32,760	25,404	63,885	52,012	107,437
Total operating costs and expenses	117,213	83,783	225,611	164,496	357,464
Operating income (loss)	(12,295)	6,668	(12,383)	3,287	30,401
Financial expenses (income), net	940	2,617	3,586	5,049	12,299
Income (loss) before income tax	(13,235)	4,051	(15,969)	(1,762)	18,102
Income tax	1,406	2,396	2,800	(7,369)	(1,706)
Net income (loss)	$ (14,641)	$ 1,655	$ (18,769)	$ 5,607	$ 19,808
Basic net income (loss) per ordinary share (in usd per share)	$ (0.14)	$ 0.02	$ (0.18)	$ 0.06	$ 0.20
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	103,484,866	100,718,893	103,061,557	100,298,230	100,930,866
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.14)	$ 0.02	$ (0.18)	$ 0.05	$ 0.18
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	103,484,866	107,647,802	103,061,557	107,897,907	108,877,648